Targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer, according to research by Wistar Institute scientists.
The Wistar Institute is opening the Center for Advanced Therapeutics to speed up the creation of new drugs and therapies for human health. The CAT is led by Paul Lieberman and capitalizes on a history of Wistar research in cancer, immunology, and infectious disease.
